

**PHARMAESSENTIA APPOINTS RODDY MCILWAIN AS SENIOR VICE PRESIDENT OF U.S. SALES AND MARKETING**

*McIlwain to position U.S. organization for rapid launch, leveraging a decorated 30-year career in pharmaceutical sales and marketing*

September 27, 2021, Burlington, MA – [PharmaEssentia Corporation](#) (TPEX: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Roddy McIlwain as Senior Vice President of Sales and Marketing for the U.S. subsidiary.

“We are thrilled to welcome such a dynamic sales and marketing leader to PharmaEssentia and are confident that Roddy will leverage his distinctive expertise to help guide a successful U.S. commercialization strategy so that we can deliver on our mission to support patient care,” said Meredith Manning, General Manager of the U.S. subsidiary. “With extensive knowledge in hematology and oncology, Roddy will provide a critical voice in our journey to be a trusted steward and partner to the U.S. MPN community.”

Prior to PharmaEssentia, Mr. McIlwain served as Vice President of Oncology-Hematology Sales at Jazz Pharmaceuticals. During his tenure, he successfully led launches for four products in the leukemia, transplant and lung cancer markets. He cultivated his earlier career in sales and marketing roles at Otsuka America Pharmaceuticals, Genentech and Ortho Biotech (now Johnson & Johnson). Mr. McIlwain received his bachelor's degree in marketing from the University of South Carolina and an Executive MBA from Webster University.

“My valued roles in sales and marketing have prepared me well for this compelling role with the esteemed PharmaEssentia team. I’m looking forward to contributing my expertise and helping to shape the trajectory of the organization as an emerging leader in the U.S. MPN community,” said Mr. McIlwain. “We have an opportunity here to bring fresh new thinking to a community in need of new solutions, and I’m eager to take on the challenge.”

**About PharmaEssentia**

PharmaEssentia Corporation (TPEX: 6446), based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product already approved in Europe and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with operations in the U.S., Japan, China and Korea, along with a world-class biologics production facility in Taichung. For more information, visit our [website](#) or find us on [LinkedIn](#) and [Twitter](#).

Media Contact:

Kellie Hotz, [kellie\\_hotz@pharmaessentia.com](mailto:kellie_hotz@pharmaessentia.com)

###